The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology

蒂施癌症研究所 (TCI) Paul Calabresi K12 临床肿瘤学职业发展奖

• 批准号: 10434380
• 负责人: Nina Bhardwaj
• 金额: $ 5.4万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10434380
• 关键词: Address; Basic Science; Cancer Intervention; Clinical; Clinical Investigator; Clinical Oncology; Clinical Research; Clinical Sciences; Clinical Trials; Data Science; Development; Doctor of Philosophy; Entrepreneurship; Environment; Evaluation; Faculty; Funding; Future; Goals; Immunotherapeutic agent; Individual; Institutes; Interdisciplinary Communication; Intervention Trial; Justice; K-Series Research Career Programs; Knowledge; Leadership; Learning; Malignant Neoplasms; Master of Science; Medicine; Mentors; Methodology; Oncologist; Oncology; Outcome; Pharmaceutical Preparations; Population; Professional Competence; Program Development; Research; Research Activity; Research Personnel; SECTM1 gene; Schools; Science; Structure; Talents; Therapeutic; Training; Training and Education; Translational Research; United States National Institutes of Health; anti-racism; anticancer research; cancer immunotherapeutics; cancer therapy; career; career development; drug discovery; education research; equity diversity and inclusion; faculty community; innovation; medical specialties; multidisciplinary; multiple omics; next generation; novel; patient oriented; patient oriented research; pedagogy; precision medicine clinical trials; programs; recruit; resilience; response; social; success; tool

SUMMARY/ABSTRACT: The purpose of our proposed Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology (K12) is to catalyze the clinical and translational research career development of inspired clinical oncologists from diverse oncology specialties and backgrounds, to become future innovative, scientifically grounded and impactful leaders in clinical cancer research and interventional trials. The intent of our K12 is to advance the careers of the next generation of independently funded interdisciplinary Scholars, armed with the methodologic and analytical acumen, scientific knowledge, teaming capacity and career skills required to successfully address specific unmet needs in cancer treatment, which significantly impact our catchment relevant population. Our strongly mentored career development 3 year program for early stage (junior faculty) investigators, will capitalize upon the Tisch Cancer Institute's expertise in cancer immunotherapeutics, novel correlates of immunotherapeutic response, integrative multi- omic platforms to inform drug repositioning approaches; outstanding cadre of Clinical and Translational Mentors; diverse pool of compelling Scholars, and an academically rigorous training environment that prepares the most compelling MD, or MD/PhD junior faculty in clinical oncology for careers in patient oriented research. Our curricular and mentored research activities will additionally leverage institutional strengths in Data Science, Drug Discovery and Precision Medicine: clinical trial methodology; innovative clinical and translational research education and pedagogy, including opportunities to earn a Master's of Science or PhD in Clinical Research, offered through the Clinical Research Education Program in the Graduate School of Biomedical Sciences and CTSA Center for Patient Oriented Research Training, Education and Development (CePORTED); and align with the NIH UNITE and our institutional anti-racist agenda and commitment to recruit and retain talented underrepresented individuals in medicine and science (URiMS). To accomplish our goals, we will pursue the following specific aims: Aim 1: Champion a structured, educational, scholar specific development program to prepare clinical oncologists to conduct cutting edge, hypothesis -driven and practice changing research in cancer therapeutics; Aim 2: Provide Co-Mentored (Basic and Clinical science faculty) and community informed clinical trial research opportunities in therapeutic innovation; Aim 3: Build a patient oriented cancer research learning culture to advance therapeutic innovation by delivering cutting edge multidisciplinary career development opportunities to advance team science, leadership, cross-disciplinary communication, resilience, and entrepreneurship; Aim 4: Advance justice, equity, diversity and inclusion as core tenets of socially responsible clinical investigators; and Aim 5: Implement a comprehensive, rigorous and quality improvement approach, to program, trainee and mentor evaluation, utilizing novel tools, to track milestones as well as outcome metrics of success.

摘要/摘要：我们拟议的Tisch癌症研究所（TCI）的目的Paul Calabresi K12 临床肿瘤学职业发展奖（K12）是催化临床和转化研究 从各种肿瘤学专业和背景的临床肿瘤学家的职业发展， 成为临床癌症研究和 介入试验。我们K12的目的是促进独立的下一代职业 资助的跨学科学者，配备了方法论和分析敏锐度，科学知识， 成功满足癌症治疗中特定未满足需求所需的团队能力和职业技能， 这重大影响我们的集水区相关人群。我们强烈指导的职业发展3 早期的年度计划（初级教师）调查员将利用Tisch Cancer Institute的 癌症免疫治疗药的专业知识，免疫治疗反应的新型相关性，综合多综合 用于通知药物重新定位方法的imic平台；出色的临床和翻译干部 导师；各种引人入胜的学者以及一个学术上严格的培训环境 最引人注目的MD或医学博士/博士学位初级教师在临床肿瘤学领域的职业中。 我们的课程和指导的研究活动将额外利用数据科学的机构优势， 药物发现和精确医学：临床试验方法；创新的临床和转化研究 教育和教育学，包括获得临床研究中科学或博士学位硕士学位的机会， 通过生物医学研究生院的临床研究教育计划提供 CTSA面向患者的研究培训，教育与发展中心（CEPORTED）；并对齐 NIH Unite和我们的机构反种族主义议程以及致力于招募和保留才华的承诺 医学和科学（URIMS）的代表人数不足。为了实现我们的目标，我们将追求 以下具体目的：目标1：倡导一个结构化的，教育，学者特定的发展计划 准备临床肿瘤学家进行前沿，假设驱动和练习改变研究 癌症治疗剂； AIM 2：提供联合授权（基础和临床科学教师）和社区知情 治疗创新方面的临床试验研究机会；目标3：建立一个以患者为导向的癌症研究 学习文化通过提供尖端的多学科职业来推进治疗创新 发展团队科学，领导力，跨学科沟通，韧性， 和企业家精神；目标4：提高正义，公平，多样性和包容性作为社会核心原则 负责任的临床研究人员；目标5：实施全面，严格和质量的改进 方法，计划，实习生和导师评估，利用新颖的工具，跟踪里程碑以及 成功的结果指标。